4'-[(2-丁基-4-氧代-1,3-二氮杂螺[4.4]壬-1-烯-3-基)甲基]-N-(4,5-二甲基-3-异恶唑基)-2'-(乙氧基甲基)-[1,1'-联苯]-2-磺酰胺
中文名称 | 4'-[(2-丁基-4-氧代-1,3-二氮杂螺[4.4]壬-1-烯-3-基)甲基]-N-(4,5-二甲基-3-异恶唑基)-2'-(乙氧基甲基)-[1,1'-联苯]-2-磺酰胺 |
---|---|
中文同义词 | 4'-[(2-丁基-4-氧代-1,3-二氮杂螺[4.4]壬-1-烯-3-基)甲基]-N-(4,5-二甲基-3-异恶唑基)-2'-(乙氧基甲基)-[1,1'-联苯]-2-磺酰胺;化合物SPARSENTAN;4'-((2-丁基-4-氧代-1,3-二氮杂螺[4.4]壬烷-1-烯-3-基)甲基)-N-(4,5-二甲基异恶唑-3-基)-2'-(乙氧基甲基)-[1,1'-联苯]-2-磺酰胺;SPARSENTAN/ 4'-[(2-丁基-4-氧代-1,3-二氮杂螺[4.4]壬-1-烯-3-基)甲基]-N-(4,5-二甲基-3-异恶唑基)-2'-(乙氧基甲基)-[1,1'-联苯]-2-磺酰胺;司巴森坦;司帕生坦;司帕生坦,4'-[(2-丁基-4-氧代-1,3-二氮杂螺[4.4]壬-1-烯-3-基)甲基]-N-(4,5-二甲基-3-异恶唑基)-2'-(乙氧基甲基)-[1,1'-联苯]-2-磺酰胺;4'-[(2-丁基-4-氧代-1,3-二氮杂螺[4.4]壬-1-烯-3-基)甲基]-N-(4,5-二甲基-3-异恶唑基)-2'-(乙氧基甲基)-[1,1'-联苯]-2-磺酰胺 8级 |
英文名称 | Sparsentan (RE-021) |
英文同义词 | 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide;Sparsentan (RE-021);Sparsentan-d5 (RE-021-d5);RE 201;[1,1'-Biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-;4'-[(2-Butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-N-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide;BMS-346567;formerly known as DARA |
CAS号 | 254740-64-2 |
分子式 | C32H40N4O5S |
分子量 | 592.75 |
EINECS号 | |
相关类别 | 抑制剂;小分子抑制剂;原料药中间体;特殊化学品 |
Mol文件 | 254740-64-2.mol |
结构式 |
4'-[(2-丁基-4-氧代-1,3-二氮杂螺[4.4]壬-1-烯-3-基)甲基]-N-(4,5-二甲基-3-异恶唑基)-2'-(乙氧基甲基)-[1,1'-联苯]-2-磺酰胺 性质
熔点 | 148 °C(Solv: isopropanol (67-63-0); water (7732-18-5)) |
---|---|
沸点 | 744.4±70.0 °C(Predicted) |
密度 | 1.28±0.1 g/cm3(Predicted) |
储存条件 | Store at -20°C |
溶解度 | 可溶于DMSO |
形态 | 结晶固体 |
酸度系数(pKa) | 7.06±0.50(Predicted) |
InChIKey | WRFHGDPIDHPWIQ-UHFFFAOYSA-N |
SMILES | C1(C2=CC=C(CN3C(=O)C4(CCCC4)N=C3CCCC)C=C2COCC)=CC=CC=C1S(NC1C(C)=C(C)ON=1)(=O)=O |
Target | Value |
endothelin type A receptor
() | |
angiotensin II type 1 receptor
() |
Sparsentan dose dependently antagonizes the angiotensin II-induced pressor response with an ED 50 value of 0.8 µmol/kg iv and 3.6 µmol/kg po. Sparsentan also shows efficacious and long acting in the big ET-1-induced pressor model. Sparsentan causes a significant lowering of blood pressure at the lowest dose tested (10 µmol/kg/day) in spontaneously hypertensive rats. Sparsentan shows good oral bioavailability in rats, dogs, and monkeys, averaging 40%, 86%, and 21% F, respectively. At 100 µmol/kg/day, Sparsentan reduces the blood pressure from 170 to less than 100 mmHg during the course of the drug’s pharmacokinetic duration. Sparsentan at 100 µmol/kg/day essentially converts the spontaneously hypertensive rats into normotensive rats during the course of its pharmacokinetic duration.
安全信息
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/04/30 | HY-17621 | Sparsentan | 1 mg | 600元 | |
2024/04/30 | HY-17621 | 4'-[(2-丁基-4-氧代-1,3-二氮杂螺[4.4]壬-1-烯-3-基)甲基]-N-(4,5-二甲基-3-异恶唑基)-2'-(乙氧基甲基)-[1,1'-联苯]-2-磺酰胺 Sparsentan | 254740-64-2 | 5mg | 1100元 |